Remove Behavioural Health Remove Development Remove FDA Approval Remove Life Science
article thumbnail

IVRHA 2022: Exhibiting pioneers of medical XR

pharmaphorum

In 2021, the behavioural health company and Sumitomo Dainippon Pharma Co. in Japan announced their partnership to develop and commercialise prescription digital therapeutics and general wellness products to treat social anxiety disorder, generalised anxiety, and major depressive disorder. About the author .